• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    President, Global Head of R&D Wang Lai was granted 427,895 units of Ordinary Shares, increasing direct ownership by 42% to 1,451,424 units (SEC Form 4)

    1/5/26 5:12:01 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONC alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Wang Lai

    (Last) (First) (Middle)
    C/O BEONE MEDICINES I GMBH
    AESCHENGRABEN 27, 21ST FLOOR

    (Street)
    BASEL V8 4051

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BeOne Medicines Ltd. [ ONC ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    President, Global Head of R&D
    3. Date of Earliest Transaction (Month/Day/Year)
    12/31/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Ordinary Shares(1) 12/31/2025 A 427,895 A $0 1,451,424 D
    Ordinary Shares 601,965 I See Footnote(2)
    RMB Shares(3) 0(4)(5) I See Footnote(5)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents securities underlying restricted share units. 1/4 of the securities will vest on each anniversary of December 31, 2025, subject to continued service through each such date. Unvested securities are subject to accelerated vesting upon certain termination events.
    2. These securities are held by Wang Holdings LLC, the limited liability company interests of which are owned by the Reporting Person, his spouse and a trust created by the Reporting Person for the benefit of his spouse and children, for which the Reporting Person disclaims beneficial ownership.
    3. The term "RMB Shares" is used herein to represent the ordinary shares, par value $0.0001 per share, of the Issuer, issued directly by the Issuer in the Issuer's initial public offering on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange (the "STAR Offering"), to permitted investors in Renminbi ("RMB") within the People's Republic of China ("PRC") in accordance with the rules of the STAR Market.
    4. The Issuer established an employee participation program ("RMB Shares Employee Participation Plan"), which allows certain executive officers and qualified employees of the Issuer's subsidiaries in the PRC to indirectly participate in the STAR Offering and purchase certain RMB Shares from the Issuer through an asset management plan administrated by China International Capital Corporation Limited in a transaction that is exempt under Rule 16b-3. The RMB Share Employee Participation Plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at the initial public offering price of RMB192.6 per RMB Share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924).
    5. The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, has contributed RMB10 million to the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose.
    Remarks:
    /s/ Qing Nian, as Attorney-in-Fact 01/05/2026
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ONC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ONC

    DatePrice TargetRatingAnalyst
    11/24/2025Buy
    Truist
    9/18/2025$385.00Overweight
    Barclays
    4/7/2025$312.00Outperform
    RBC Capital Mkts
    3/3/2025$207.00 → $320.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $ONC
    SEC Filings

    View All

    BeOne Medicines Ltd. filed SEC Form 8-K: Termination of a Material Definitive Agreement

    8-K - BeOne Medicines Ltd. (0001651308) (Filer)

    12/19/25 6:01:09 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeOne Medicines Ltd. filed SEC Form 8-K: Leadership Update

    8-K - BeOne Medicines Ltd. (0001651308) (Filer)

    12/18/25 6:02:54 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by BeOne Medicines Ltd.

    144 - BeOne Medicines Ltd. (0001651308) (Subject)

    12/15/25 4:32:14 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, General Counsel Lee Chan Henry exercised 664 units of American Depositary Shares at a strike of $191.56 and sold $220,289 worth of American Depositary Shares (664 units at $331.76) (SEC Form 4)

    4 - BeOne Medicines Ltd. (0001651308) (Issuer)

    1/9/26 5:15:55 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, Global Head of R&D Wang Lai was granted 427,895 units of Ordinary Shares, increasing direct ownership by 42% to 1,451,424 units (SEC Form 4)

    4 - BeOne Medicines Ltd. (0001651308) (Issuer)

    1/5/26 5:12:01 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Oyler John sold $30,659,419 worth of American Depositary Shares (100,000 units at $306.59), closing all direct ownership in the company (SEC Form 4)

    4 - BeOne Medicines Ltd. (0001651308) (Issuer)

    12/17/25 4:47:31 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA

    Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 status High GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impact Results to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+)

    1/6/26 1:30:00 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

    BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company's website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patient

    12/23/25 6:01:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

    BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. "The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in se

    12/18/25 6:00:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on BeOne Medicines

    Truist initiated coverage of BeOne Medicines with a rating of Buy

    11/24/25 8:30:57 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on BeOne Medicines with a new price target

    Barclays initiated coverage of BeOne Medicines with a rating of Overweight and set a new price target of $385.00

    9/18/25 8:38:35 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on BeiGene with a new price target

    RBC Capital Mkts initiated coverage of BeiGene with a rating of Outperform and set a new price target of $312.00

    4/7/25 8:43:36 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONC
    Financials

    Live finance-specific insights

    View All

    BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates

    Third quarter total revenues increased 41% to $1.4 billion versus third quarter 2024 Global BRUKINSA® (zanubrutinib) revenues increased 51% to $1.0 billion versus third quarter 2024 Diluted GAAP Earnings per American Depository Share (ADS) of $1.09, non-GAAP diluted Earnings per ADS of $2.65 47 abstracts accepted at American Society of Hematology (ASH) Annual Meeting BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced financial results and corporate updates from the third quarter of 2025. "These strong financial results reinforce our position as a global oncology leader with exceptional topline growth and a strong balance sheet,

    11/6/25 6:00:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates

    Second quarter total revenues increased 42% to $1.3 billion versus second quarter 2024 Global BRUKINSA revenues increased 49% to $950 million versus second quarter 2024 Reported diluted GAAP Earnings per American Depositary Share (ADS) of $0.84, non-GAAP diluted Earnings per ADS of $2.25 Anticipate 20+ milestones in next 18 months across hematology and solid tumor pipeline BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced financial results and corporate updates from the second quarter of 2025. "Our strong second quarter performance reinforces our trajectory as a global oncology powerhouse and underscores our proven abilit

    8/6/25 6:00:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeiGene Announces First Quarter 2025 Financial Results and Business Updates

    First quarter 2025 total revenues increased 49% to $1.1 billion with BRUKINSA® (zanubrutinib) global sales increasing 62% to $792 million on strong demand growth versus first quarter 2024 Achieved GAAP profitability and significantly improved operating cash flow Advanced late-stage hematology and solid tumor pipelines with plan to host Investor R&D Day on June 26 Secured shareholder approval to rename the Company to BeOne Medicines Ltd. and redomicile to Switzerland BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025.

    5/7/25 6:00:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONC
    Leadership Updates

    Live Leadership Updates

    View All

    The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

    DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man

    10/21/25 8:05:00 AM ET
    $CRVS
    $DNA
    $EXEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)